keyword
MENU ▼
Read by QxMD icon Read
search

Innohep

keyword
https://www.readbyqxmd.com/read/22310458/low-molecular-weight-heparin-gels-based-on-nanoparticles-for-topical-delivery
#1
C Loira-Pastoriza, A Sapin-Minet, R Diab, J L Grossiord, P Maincent
A commercial suspension of nanoparticles (Eudragit RS 30D) was used to manufacture a gel for topical application. Gels were prepared by mixing a polycationic polymer (Eudragit(®) RS 30D) and a low molecular weight heparin (LMWH), an antithrombotic agent. Gels formed spontaneously at a ratio of 1:1 as a result of electrostatic interactions between the polyanionic drug and the polycationic polymer. Different types of heparin were used: Bemiparin, Enoxaparin (Lovenox), Nadroparin (Fraxiparin) and Tinzaparin (Innohep)...
April 15, 2012: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/21819539/no-accumulation-of-the-peak-anti-factor-xa-activity-of-tinzaparin-in-elderly-patients-with-moderate-to-severe-renal-impairment-the-iris-substudy
#2
RANDOMIZED CONTROLLED TRIAL
V Siguret, I Gouin-Thibault, E Pautas, A Leizorovicz
BACKGROUND: In the elderly, concerns have been raised regarding the risk of accumulation of low molecular weight heparins, owing to their renal elimination. Although data exist for tinzaparin, they are observational. OBJECTIVES: To assess whether: (i) there was an accumulation of anti-factor Xa activity; and (ii) there was any relationship between anti-FXa activity and age, weight, creatinine clearance or clinical outcomes in patients with moderate-to-severe renal impairment receiving tinzaparin (175 IU kg(-1) per 24 h) for acute venous thromboembolism...
October 2011: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/21477846/safety-profile-of-tinzaparin-versus-subcutaneous-unfractionated-heparin-in-elderly-patients-with-impaired-renal-function-treated-for-acute-deep-vein-thrombosis-the-innohep%C3%A2-in-renal-insufficiency-study-iris
#3
RANDOMIZED CONTROLLED TRIAL
Alain Leizorovicz, Virginie Siguret, Dominique Mottier, Alain Leizorovicz, Virginie Siguret, Dominique Mottier, Fabrice Clonier, Mette Janas, John Stinson, Grace Townshend, Michael Maddalena
INTRODUCTION: Trials comparing the use of full dose unfractionated heparin (UFH) or low molecular weight heparins (LMWHs) in very elderly patients with impaired renal function are lacking. IRIS aimed to assess whether LMWH is at least as safe as UFH in this population. MATERIALS AND METHODS: The study included renally impaired patients ≥70 years with acute symptomatic lower limb deep vein thrombosis (DVT). Patients were randomized to initial treatment with either tinzaparin 175 IU/kg once daily (n=269) or activated partial thromboplastin time-adjusted UFH twice daily (n=270)...
July 2011: Thrombosis Research
https://www.readbyqxmd.com/read/20568836/tinzaparin-sodium-a-review-of-its-use-in-the-prevention-and-treatment-of-deep-vein-thrombosis-and-pulmonary-embolism-and-in-the-prevention-of-clotting-in-the-extracorporeal-circuit-during-haemodialysis
#4
REVIEW
Sheridan M Hoy, Lesley J Scott, Greg L Plosker
Tinzaparin sodium (Innohep) is a low molecular weight heparin (LMWH) that is effective in the prevention and treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and in maintaining the patency of haemodialysis circuits in adult patients. In terms of preventing DVT and/or PE, therapy with subcutaneous tinzaparin sodium was more effective than oral warfarin and equivalent to subcutaneous enoxaparin sodium in patients undergoing orthopaedic surgery, and did not significantly differ from that of subcutaneous unfractionated heparin (UFH) in patients undergoing general surgery...
July 9, 2010: Drugs
https://www.readbyqxmd.com/read/20061691/profile-of-low-molecular-weight-tinzaparin-sodium-for-anticoagulation-during-hemodialysis
#5
COMPARATIVE STUDY
Khalid A Al-Saran, Alaa Sabry, Moammer Taha, Mamdouh Abdul Ghafour, Fawzan Al Fawzan
Low-molecular-weight heparin (LMWH) has been suggested as providing safe, efficient, convenient, and possibly more cost-effective anticoagulation for hemodialysis (HD) than unfractionated heparin (UFH) with a single bolus dose at the start of hemodialysis effectively prevents clot formation in the dialyzer and bubble trap with fewer side-effects and possible benefits on uremic dyslipidemia. In this study, we compared the safety, clinical efficacy, and cost effectiveness of tinzaparin sodium (Innohep) with unfractionated heparin (UFH) in 23 chronic HD patients; their extracorporeal anticoagulant protocol consisted of UFH was switched to tinzaparin for a period of 6 months...
January 2010: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/18832911/efficacy-and-safety-of-once-daily-low-molecular-weight-heparin-tinzaparin-sodium-in-high-risk-pregnancy
#6
Fionnuala Ní Ainle, Audris Wong, Niamh Appleby, Brigitte Byrne, Carmen Regan, Tayyaba Hassan, Marie Milner, Ann O Sullivan, Barry White, James O'Donnell
Low molecular weight heparin (LMWH) is widely regarded as the anticoagulant treatment of choice for the prevention and treatment of venous thromboembolism during pregnancy. However, previous studies have demonstrated that the pharmacokinetic profiles of LMWH vary significantly with increasing gestation. Consequently, it remains unclear whether LMWH regimens recommended for use in nonpregnant individuals can be safely extrapolated to pregnant women. The aims of this study were to assess the safety and the efficacy of tinzaparin sodium (Innohep) administered only once daily during pregnancy...
October 2008: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/17721622/reduction-of-painful-vaso-occlusive-crisis-of-sickle-cell-anaemia-by-tinzaparin-in-a-double-blind-randomized-trial
#7
RANDOMIZED CONTROLLED TRIAL
Mohamad Hasan Qari, Soad Khalil Aljaouni, Mohamad Salleh Alardawi, Huda Fatani, Fatin Mohamad Alsayes, Panagiotis Zografos, Mohamad Alsaigh, Adnan Alalfi, Mohamad Alamin, Abdulilah Gadi, Shaker A Mousa
A randomized double-blind clinical trial was performed to test the safety and efficacy of a low-molecular-weight heparin, tinzaparin (Innohep), for the management of acute painful vasoocclusive crisis characteristic of sickle cell anemia (SCA). We studied 253 patients with acute painful crisis but with no other complications of SCA, randomized to treatment or control groups. In the treatment group, 127 patients received tinzaparin at 175 IU/kg, subcutaneous once daily, along with supportive care including morphine analgesia; in the control group, 126 patients received placebo and the same supportive care...
August 2007: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/16868144/glycosaminoglycans-increase-levels-of-free-and-bioactive-igf-i-in-vitro
#8
Anne Vestergård Møller, Søren Peter Jørgensen, Jian-Wen Chen, Anni Larnkjaer, Thomas Ledet, Allan Flyvbjerg, Jan Frystyk
BACKGROUND: It is unclear how IGFs become separated from their IGF-binding proteins (IGFBPs) in vivo. However, the IGFBPs possess binding sites for glycosaminoglycans (GAGs) and interaction with GAGs alters IGFBP ligand affinity. Accordingly, GAGs may control IGF bioavailability. To test this hypothesis, we investigated the effect of GAGs on serum levels of free and bioactive IGF-I, total IGF-I, and IGFBPs in vitro. METHODS: Serum was incubated with increasing concentrations of six different GAGs (heparin, tinzaparin (Innohep), dermatan sulfate, heparan sulfate, non-anticoagulant (nac) heparin, and nac low-molecular weight heparin)...
August 2006: European Journal of Endocrinology
https://www.readbyqxmd.com/read/15212562/tinzaparin-sodium-a-review-of-its-pharmacology-and-clinical-use-in-the-prophylaxis-and-treatment-of-thromboembolic-disease
#9
REVIEW
Susan M Cheer, Christopher J Dunn, Rachel Foster
Tinzaparin sodium (tinzaparin; innohep) is a low molecular weight heparin (LMWH) formed by the enzymatic degradation of porcine unfractionated heparin (UFH). In clinical trials, once-daily subcutaneous (SC) tinzaparin was effective and generally well tolerated in the prophylaxis and treatment of thromboembolic disease. SC tinzaparin 75 anti-Xa IU/kg/day showed similar thromboprophylactic efficacy to adjusted-dosage oral warfarin in patients undergoing total hip arthroplasty; in patients undergoing knee replacement, the incidence of deep vein thrombosis (DVT) was significantly lower with tinzaparin...
2004: Drugs
https://www.readbyqxmd.com/read/15080848/low-molecular-weight-heparin-tinzaparin-vs-placebo-in-the-treatment-of-mild-to-moderately-active-ulcerative-colitis
#10
RANDOMIZED CONTROLLED TRIAL
S Bloom, S Kiilerich, M R Lassen, A Forbes, K Leiper, E Langholz, E J Irvine, C O'Morain, D Lowson, S Orm
BACKGROUND: Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis. AIM: To test whether low molecular weight heparin, given subcutaneously, would provide a significant therapeutic response compared with placebo in the treatment of mild to moderate ulcerative colitis. STUDY DESIGN: A prospective, double-blind, randomized, placebo-controlled, multi-centre trial comparing tinzaparin 175 anti-Xa IU/kg/day (innohep, LEO Pharma) subcutaneously for 14 days followed by tinzaparin 4500 anti-Xa IU/day subcutaneously for 28 days with placebo, administered subcutaneously once daily for up to 42 days...
April 15, 2004: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/12529961/specific-and-non-specific-kgf-inhibition-of-kgf-induced-breast-cancer-cell-motility
#11
Xiao-Ping Zang, Thao-Nguyen Nguyen, J Thomas Pento
BACKGROUND: Keratinocyte growth factor (KGF), a member of the fibroblast growth factor family, is a mesenchymally derived mediator of epithelial cell proliferation and migration. In a previous study, we reported that KGF enhanced the motility of human breast cancer cells. The objective of the present study was to examine the influence of specific and non-specific KGF inhibitors on KGF-induced motility and proliferation in ER-positive MCF-7 cells. MATERIALS AND METHODS: In the present study three KGF inhibitors were employed [Heparin, Innohep, a low molecular weight heparin (LMWH) and KGFR2 beta (IIIb)/Fc, a chimeric KGFR fragment]...
September 2002: Anticancer Research
https://www.readbyqxmd.com/read/12214150/home-treatment-of-deep-vein-thrombosis-an-out-patient-treatment-model-with-once-daily-injection-of-low-molecular-weight-heparin-tinzaparin-in-555-patients
#12
Leif Lapidus, Jens Börretzen, Martin Fahlén, Hans Grönlund Thomsen, Sverker Hasselblom, Lars Larson, Henrik Nordström, Lennart Stigendal, Lotte Waller
During a 22-month period, 555 consecutive patients at seven hospitals in the western part of Sweden with an acute deep vein thrombosis (DVT) not involving the iliac vein and not having pulmonary embolism were included in a study testing the efficacy of implementing out-patient treatment. For all patients with a confirmed diagnosis of acute DVT, a folder was used that contained two checklists with detailed instructions for further treatment, one for the doctor and one for the nurse, an information pamphlet for the patient and prepared prescriptions for low-molecular-weight heparin (LMWH) tinzaparin (Innohep) of 175 anti-Xa IU/kg body weight subcutaneously once daily and warfarin...
March 2002: Pathophysiology of Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/12200805/intravenous-and-subcutaneous-weight-based-dosing-of-the-low-molecular-weight-heparin-tinzaparin-innohep-in-end-stage-renal-disease-patients-undergoing-chronic-hemodialysis
#13
MULTICENTER STUDY
James W Hainer, Donald J Sherrard, Suzanne K Swan, Jeffrey S Barrett, Christopher A Assaid, Michael J Fossler, Donna S Cox, Robert M Williams, Amy L Pittenger, Carol A Stephenson, Tsushung A Hua
BACKGROUND: Patients with end-stage renal disease are subject to a broad range of thrombotic complications. Low molecular weight heparins (LMWHs) are effective antithrombotic agents; however, they are cleared largely by renal mechanisms, raising uncertainty about their use in renally impaired patients. METHODS: Twelve chronic hemodialysis subjects were administered two single doses of the LMWH tinzaparin, 75 IU/kg, 2 weeks apart: subcutaneously (SC) on an off-dialysis day and intravenously (IV) just before dialysis...
September 2002: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/12091045/low-molecular-weight-heparin-innohep-as-thromboprophylaxis-in-outpatients-with-a-plaster-cast-a-venografic-controlled-study
#14
RANDOMIZED CONTROLLED TRIAL
Per Seest Jørgensen, Torsten Warming, Kim Hansen, Charlotte Paltved, Helle Vibeke Berg, René Jensen, René Kirchhoff-Jensen, Lasse Kjaer, Nina Kerbouche, Per Leth-Espensen, Eva Narvestad, Søren Wistisen Rasmussen, Carsten Sloth, Carsten Tørholm, Peer Wille-Jørgensen
INTRODUCTION: The aim of this study was to investigate the incidence of deep vein thrombosis (DVT) in patients immobilized in plaster cast and the possible efficacy of prophylaxis with low molecular weight heparin (LMWH). MATERIAL AND METHODS: The study was a randomized, assessor-blinded, open multicenter (three centers) study. All patients over 18 years of age with planned plaster cast on a lower extremity of at least 3 weeks were eligible for participation. Written informed consent was obtained from 300 patients and they were randomized to either 3...
March 15, 2002: Thrombosis Research
https://www.readbyqxmd.com/read/11703412/the-outcome-of-ambulatory-dvt-management-using-a-multidisciplinary-approach
#15
MULTICENTER STUDY
P Rose, D Bell, E S Green, A Davenport, C Fegan, H Grech, D O'Shaughnessy, J Voke
Low molecular weight heparins (LMWHs) have been demonstrated to be at least as safe and effective as unfractionated heparin (UFH) in the initial management of deep vein thrombosis (DVT). However, the effectiveness of using LMWH in the ambulatory management of DVT in a 'real-life' setting has yet to be evaluated. This multicentre retrospective study involving 697 patients considers the outcome data of patients under- going ambulatory DVT treatment with tinzaparin (Innohep(R), Leo Pharmaceuticals, Risborough, Buckinghamshire, UK)...
October 2001: Clinical and Laboratory Haematology
https://www.readbyqxmd.com/read/11399579/haemostasis-and-thrombosis-current-clinical-practice-low-molecular-weight-heparins-in-the-prophylaxis-and-treatment-of-thrombo-embolic-disease
#16
DENISE F. O'Shaughnessy
Low-Molecular-Weight Heparin (LMWH) fractions are prepared from standard unfractionated heparin (UFH) and are thus similar to it in many aspects. The major advantages of LMWH are improved efficacy and safety, longer half-life and reduced need for laboratory monitoring. In addition, the dangers of UFH administered by continuous infusion in the hospital setting are often not fully appreciated and the necessary monitoring and dosage adjustment poorly carried out resulting in inadequate doses being given. LMWHs are the drug of choice in many clinical situations...
2000: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/11127859/elderly-patients-treated-with-tinzaparin-innohep-administered-once-daily-175-anti-xa-iu-kg-anti-xa-and-anti-iia-activities-over-10-days
#17
V Siguret, E Pautas, M Février, C Wipff, B Durand-Gasselin, M Laurent, J P Andreux, M d'Urso, P Gaussem
Since low molecular weight heparins (LMWH) are partly eliminated by renal excretion, their pharmacodynamic profile may be modified in very elderly patients with age-related renal impairment. The aim of this prospective study was to determine whether tinzaparin (Innohep) 175 anti-Xa IU/kg administered subcutaneously once daily over 10 days does accumulate in hospital patients greater than 70 years of age. Plasma anti-Xa and anti-IIa amidolytic levels and APTT were determined prior to the first injection (day 0), and then, at peak level i...
November 2000: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/9702313/dose-titration-study-of-tinzaparin-a-low-molecular-weight-heparin-in-patients-on-chronic-hemodialysis
#18
M Egfjord, L Rosenlund, B Hedegaard, H L Buchardt, C Stengel, P Gardar, L Andersen, L Andersen
The minimal necessary dose of Innohep (IH) (MNDI) (Innohep [tinzaparin], Leo Pharmaceutical Corp., Ballerup, Denmark) was examined in 40 patients switched from conventional heparin ([CH], Leo Pharmaceutical Corp.) to IH and in 13 patients already treated with IH. Clotting in the venous chamber and in the dialyzer was evaluated on a 4 point scale by visual inspection. IH was administrated as a bolus injection into the arterial side of the dialyzer at the beginning of dialysis sessions. The initial dose of IH was 50% of the total dose of CH used before the study (in respective IU)...
August 1998: Artificial Organs
https://www.readbyqxmd.com/read/9119288/long-term-use-of-the-low-molecular-weight-heparin-tinzaparin-in-haemodialysis
#19
H K Simpson, J Baird, M Allison, J D Briggs, P A Rowe, M Welsh, A I Macdougall, A C Grant, G D Lowe, A Rumley, M Wallace, A P Menday
Fifty-two patients with chronic renal failure undergoing hospital haemodialysis were given a single bolus dose of tinzaparin (Innohep, Leo Laboratories, UK) into the arterial side of the dialyser, for up to 43 consecutive dialyses. The mean tinzaparin dose at the beginning was 2,139 IU anti-Xa and at the end 2,186 IU anti-Xa. Overall, tinzaparin proved a satisfactory anticoagulant for 1,370 (96.0%) out of 1,427 dialyses. Significant clot formation was prevented in 1,326 (92.8%) out of 1,429 dialyses. The clinically effective dose was associated with a mean plasma anti-Xa activity 1 h after dosing of 0...
March 1996: Haemostasis
https://www.readbyqxmd.com/read/1745997/dose-finding-study-of-a-low-molecular-weight-heparin-innohep-in-haemodialysis
#20
RANDOMIZED CONTROLLED TRIAL
K E Ryan, D A Lane, A Flynn, J Shepperd, H A Ireland, J R Curtis
A pilot investigation was performed with Innohep, a low molecular weight (LMWH) preparation (peak maximum molecular mass 3,000-6,000), to determine possible dose regimens for patients undergoing regular maintenance haemodialysis for chronic renal failure. Results from this study suggested that suppression of macroscopic clot formation and fibrinopeptide A (FPA), a marker of fibrin formation, could be achieved following bolus injections rather than bolus injections and an infusion. On the basis of these preliminary findings, a randomised crossover study was performed in eight patients undergoing regular maintenance haemodialysis for 5-7 h to determine the effective antithrombotic dose of this LMWH...
September 2, 1991: Thrombosis and Haemostasis
keyword
keyword
25731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"